CoJourney is a contract development and manufacturing organization (CDMO) specializing in the production of plasmids, viral vectors, and mRNA for gene therapies using its Zero Chrom® platform, which ensures high purity and low contamination risk. The company addresses the challenges of speed, cost, and scalability in gene therapy manufacturing by providing robust, cGMP-compliant solutions across its three dedicated facilities.
Funding
Funding not disclosed
Founders
Product
Problem
Gene therapy manufacturing faces challenges related to speed, cost, scalability, and purity, hindering the efficient production of plasmids, viral vectors, and mRNA required for clinical and commercial applications. Traditional manufacturing processes often struggle to meet the stringent regulatory requirements and cost-effectively produce high-quality materials.
Solution
CoJourney is a contract development and manufacturing organization (CDMO) that specializes in overcoming these challenges by providing robust, scalable, and cGMP-compliant manufacturing solutions for gene therapies. Utilizing its Zero Chrom® plasmid platform and advanced viral vector manufacturing platforms, CoJourney ensures high purity, high yield, and reduced contamination risk. The company offers comprehensive services, including process development, analytical method development, and GMP manufacturing for plasmids, viral vectors, and mRNA, supported by regulatory expertise to accelerate the drug development journey. CoJourney's state-of-the-art facilities and quality systems are designed to meet FDA, EMA, and NMPA standards, ensuring product quality and compliance.
Target Audience
CoJourney serves gene therapy companies worldwide, from early-stage biotechs to large pharmaceutical firms, that require reliable and scalable manufacturing solutions for plasmids, viral vectors, and mRNA.
Features
- Zero Chrom® plasmid platform for high-purity plasmid production at a lower cost
- cGMP manufacturing for plasmids, viral vectors (AAV, lentivirus, etc.), and mRNA
- Process development and optimization for increased predictability, speed, and cost-efficiency
- Analytical services, including assay development, characterization, lot release, and stability testing
- Multi-product GMP facilities designed to meet FDA/EMA/NMPA standards
- Proven track record of IND approvals with the FDA and CDE
- Scalable bioreactors for viral vector production (up to 500L, with future capacity up to 2000L)
- Comprehensive QC testing aligned with the latest regulatory standards